Goldline Pharmaceutical IPO Sees Overwhelming Demand in Third Bidding Day, Exceeds 211 Times Subscription

Goldline Pharmaceutical IPO Witnesses Strong Response

The initial public offering (IPO) of Goldline Pharmaceutical began on Tuesday, 12 May, and will conclude on Thursday, 14 May. The company has set a price band of ₹41 to ₹43 per equity share, with a face value of ₹10 per share. Investors can bid for a minimum of 3,000 equity shares, with the option to acquire additional shares in increments of 3,000.

Goldline Pharmaceuticals markets pharmaceutical products under its flagship "Goldline" brand, offering a diversified portfolio across multiple therapeutic segments. Its product range is structured into five categories: Goldline Pharma, which includes 42 products catering to specialties such as orthopedics, gastroenterology, neurology, and urology; Goldline Cardinal, comprising 54 products focused on cardiology, endocrinology, and general medicine; Goldline Aayushman, with 18 products targeting pediatric and neonatal care; Goldline InLife, offering 22 products for critical care and super-specialty treatments; and Goldline Wellness, which includes 10 products aimed at supportive care, particularly in oncology.

The company employs an asset-light approach and does not produce its own products. Instead, it collaborates with external manufacturers to develop medicines in line with its market analysis and specifications, ensuring they meet regulatory requirements and quality standards. All products are marketed under the Goldline brand through a distribution network that links to retailers and wholesalers. At present, the company works with 15 manufacturers and 7 distributors, and assists hospitals and healthcare providers with procurement and supply.

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Goldline Pharmaceuticals has established its presence in various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.

The grey market premium (GMP) for Goldline Pharmaceutical IPO today is +25. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Goldline Pharmaceutical share price is indicated at ₹68 apiece, which is 58.14% higher than the IPO price of ₹43. The minimum GMP recorded is ₹0.00, while the maximum is ₹25, according to experts.

The grey market premium indicates investors' readiness to pay more than the issue price.

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

As of day 3, the subscription status for Goldline Pharmaceutical IPO was 211.41x. The retail portion was subscribed at 264.47x, the NII portion was booked at 365.75x, and the Qualified Institutional Buyers (QIBs) portion received 11.52x of the bids. The company has received bids for 38,68,89,000 shares against 18,30,000 shares on offer at 11:54 IST, according to BSE data.

Goldline Pharmaceutical is offering an IPO valued at ₹11.61 crore through a book-building process. This IPO comprises solely a fresh issuance of 27 lakh shares. The main goal of the IPO is to repay ₹8.35 crore in loans, with the remainder allocated to general corporate needs. By March 2026, the company had total outstanding debts of ₹9.13 crore.

Cumulative Capital Pvt. Ltd serves as the book-running lead manager for the offering, while Bigshare Services Pvt. Ltd acts as the registrar. Nirman Share Brokers Pvt. Ltd is designated as the market maker for the IPO.